



The Relationship Between Prevalence of Antibiotics Resistance and Virulence Factors Genes of MRSA and MSSA Strains Isolated from Clinical Samples, West Iran

Mohammad Reza Arabestani^{1,2*}, Sahar Rastiyani¹, Mohammad Yousef Alikhani¹ and Seyed Fazlullah Mousavi³

¹Department of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran

²Nutrition Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

³Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran

ARTICLE INFO

Article history:

Received: 12 October 2017

Accepted: 25 November 2017

Online:

DOI 10.5001/omj.2018.25

Keywords:

Methicillin-Resistant

Staphylococcus aureus; Antibiotic;

Staphylococcal Enterotoxins.

ABSTRACT

Objectives: We sought to evaluate the relationship between the prevalence of antibiotics resistance and virulence factors genes in methicillin-resistant *Staphylococcal aureus* (MRSA) and methicillin-sensitive *S. aureus* (MSSA) strains from clinical samples taken in west Iran. **Methods:** We performed a cross-sectional study using 100 MRSA and 100 MSSA samples isolated from clinical specimens. We used biochemical methods to identify the isolates, which were confirmed by the polymerase chain reaction (PCR) assay. Antibiotic susceptibility testing was performed using disk diffusion. PCR detected the presence of virulence factors, including enterotoxin genes, toxic shock syndrome toxin-1 (*TSST-1*), and exfoliative toxin. **Results:** The majority of MRSA isolates exhibited a high level of resistance to common antibiotics and susceptible to vancomycin, while most MSSA isolates were also resistant to erythromycin and ciprofloxacin. The prevalence of Staphylococcal enterotoxins (SEs) were reported 147 (73.5%). Among 100 MRSA samples, 92 (92.0%) harbored *SAg* genes. The most frequent toxin gene was *sea* (45.0%) followed by *sec* (39.0%). Among 100 MSSA isolates, 89 (89.0%) harbored *SAg* genes and the most prevalent genes were *sea* (42.0%), *sek* (38.0%), *sec* (35.0%), and *TSST-1* (10.0%). The prevalence of *TSST-1* and exfoliative toxin genes in MRSA samples were 12 (12.0%). The association of *SAg* genes with MRSA and MSSA isolates showed a high prevalence of enterotoxin *seq*, *seg*, and *sei* in MRSA than MSSA with a statistically significant difference ($p < 0.050$). **Conclusions:** The prevalence of MRSA and the association of pathogenic agents with antibiotics resistance genes can lead to the emergence of strains with higher pathogenicity and less susceptibility.

Staphylococcus aureus isolates have evolved as common pathogens linked to serious community and hospital-acquired infections and have been considered as a major public health problem throughout the world for a long time.¹ These organisms express a wide range of virulence factors implicated in bacteria pathogenesis including surface attachment proteins which facilitate their adherence to injured tissues.² Depending on the strain, *S. aureus* is capable of secreting enzymes such as thermonuclease, lipase, hyaluronidase, and hemolysin. *S. aureus* is often present in food products,³ and is one of the causes of bacterial foodborne intoxications via the output of staphylococcal enterotoxins (SEs), which are heat-stable and act as superantigens.⁴ Furthermore,

S. aureus is a human commensal colonizer and the nasal carriage is a frequent route of nosocomial infection transmission.

S. aureus can quickly gain resistance to a variety of antimicrobials such as methicillin. The first evidence of methicillin-resistant *S. aureus* (MRSA) isolates arrival was in 1961.^{5,6} Nowadays, MRSA has become a major cause of hospital-associated infections worldwide.⁷ There is an alarming increase in community-acquired MRSA (CA-MRSA) infections.⁷ Most strains of *S. aureus* code superantigens, including *SEA* to *SEE*, *SEG* to *SER*, *SEU*, and toxic shock syndrome toxin -1 (*TSST-1*).⁸ Most of these superantigens are encoded by genes located on mobile genetic elements or comprising insertion elements or plasmids or transposons,

*Corresponding author: ✉mohammad.arabestani@gmail.com

so-called pathogenicity islands (e.g., *TSST-1* and some enterotoxins) or lysogenic bacteriophages.⁹

Superantigens that induce vomiting in a primate model are designated the classical SE type. Those that lack the activity or have not been implicated in this condition are classified as the SE-like (SEIs) type.¹⁰ The staphylococcal enterotoxin F (SEF) lacks emetic activity, but it is associated with *TSST-1*.¹¹ Other studies have exhibited that staphylococcal phage Q3 carries *sea* (in strain Mu50), *sep* (strain N315), or in case of *sea-sek-seq* (strain MW2) genes.¹² On the other hand, a family of pathogenicity islands carry *seb-sek-seq* (e.g., SaPI1 in strain COL), *TSST-sec3-sel* (SaPI2 in strains N315 and Mu50), or *sec-sel* (SaPI3 in strain MW2).¹³ The locus encoding the enterotoxins SEG, SEI, SEM, SEN, and SEO is currently known as *egc* (enterotoxin gene cluster).¹⁴ It is intriguing that the prevalence of *egc* gene in isolate of *S. aureus* seems to be negatively correlated with the severity of infection. For SEA, the situation is precisely the opposite: the toxin gene is significantly more often present among invasive isolates.¹⁵

This study deals with development of a rapid, reliable and low-cost polymerase chain reaction (PCR)-based protocol for the detection of most known SE genes, the *TSST-1* gene, exfoliative toxins, and *egc* in *Staphylococcus* spp.

METHODS

Two-hundred clinical samples were collected from July 2013 to June 2014 in Beheshti, Besat, Sina, and Fatemeh Hospitals, Hamadan, Iran, as shown in Table 1. The isolates were identified at species level using routine microbiological methods and *S. aureus* ATCC 25423 and *S. epidermidis* were used as positive and negative controls, respectively. PCR targeting of *nuc* and *mecA* genes were used to confirm phenotypic speciation and methicillin resistance.¹⁶

Antibiotic susceptibility testing were carried out using the Kirby-Bauer disk diffusion technique according to Clinical and Laboratory Standard Institute 2013 guidelines,¹⁷ Applied antibiotics (Mast, England) including cefoxitin 30 µg, tetracycline (TE) 10 µg, gentamycin (GM) 10 µg, erythromycin (E) 15 µg, vancomycin (VAN) 30 µg, amikacin (AK) 30 µg, imipenem (IMP) 10 µg, linezolid (LZ) 10 µg, tigecycline (TG) 15 µg, ciprofloxacin (CIP) 5 µg, clindamycin (CD) 2 µg, tobramycin (TO) 10 µg, rifampin (RF) 5 µg, and

trimethoprim/sulfamethoxazole (TMP/SMX) 1.25/23.75 µg. Methicillin resistance was examined using cefoxitin disk and confirmed by the *mecA*-specific PCR.

Total DNA was extracted using the DNA extraction Kit (BioFlux Co., Japan), according to the manufacturer's instructions. Quality of extracted DNA was assessed spectrophotometrically by the Nanodrop ND-1000 (Nanodrop Technologies, Inc., Wilmington, DE, USA). Following the DNA extraction, PCR targeting of *nuc* gene was used for confirmation of *S. aureus* strains. PCR was carried out in a final volume of a 20 µL reaction mixture containing 10 µL of 2X Taq premix Mastermix (Parstous Biotech Co., Iran), 5 µL of sterile double distilled water, 1 µL of forward primer, 1 µL of reverse primer, and 3 µL of DNA sample. The DNA of samples, as well as the DNA of positive control (*S. aureus* ATCC 25423) and a negative control (*S. epidermidis*), were amplified by an initial denaturation step for 5 minutes at 94 °C followed by 35 cycles of 94 °C for 60 seconds, 50 °C for 60 seconds, and 72 °C for 1 minute and a final extension step at 72 °C for 10 minutes in a Bio-Rad Thermal Cycler (Bio-Rad Laboratories, Inc., USA). The products PCR were subjected to 1.5% agarose gel electrophoresis.

The PCR assay targeting *mecA* gene coding methicillin resistance was performed for all isolates. Primer sequences included: forward (5'-GTAGAAATGACTGAACGTCCGATAA-3') and reverse (5'-CCAATTCCACATTGTTTCGGTCTAA-3'). *S. aureus* ATCC 25923 was included as the positive control. PCR was carried out in a final volume of a 20 µL. The initial denaturation was at 92 °C for 5 minutes. Denaturation at 94 °C for 60 seconds, annealing at 56 °C for 1 minute, and extension at 72 °C for 1 minute was maintained for 35 cycles.

Each isolate was tested by seven multiplex PCRs according to the method of Holtfreter for the genes: (i) *sea*, *seh*, and *seo*; (ii) *sed*, *etd*, and *eta*; (iii) *see*, *seb*, and *sem*; (iv) *sen*, *seq*, and *sej*; (v) *ser*, *seu*, and *sep*; (vi) *sel*, *sei*, and *TSST*; and (vii) *seg*, *sek*, and *sec*. Primers sequences are provided in Table 2. The reaction mixture for the PCR assay was 20 µL, and was prepared as previously described. DNA denaturation at 95 °C for 5 minutes was followed by 35 cycles of amplification (95 °C for 30 seconds, 55 °C for 30 seconds, and 72 °C for 60 seconds), ending with a final extension at 72 °C for 10 minutes.^{18,19}

Table 1: Primer sequences.

Gene	Target genes	Primer sequence (5'-3')	PCR product (bp)
Multiplex 1	<i>sea</i>	F: GAAAAAAGTCTGAATTGCAGGGAACA	560
	<i>seh</i>	R: CAAATAAATCGTAAT TAACCGAAGGTTC	780
	<i>seo</i>	F: CAATCACATCATAT GCGAAAGCAG R: CATCTACCCAAAC ATTAGCACC F: AGTTTGTGTAAGAAG TCAAGTGTA R: ATCTTTAAATTCAGC AGATATCCATCTAAC	180
Multiplex 2	<i>sed</i>	F: GAATTAAGTAGTACC	492
	<i>etd</i>	GCGCTAAATAATATG	358
	<i>eta</i>	R: GCTGTATTTTTCC TCCGAGAT F: CAAACTATCATGTAT CAAGGATGG R: CCAGAAATTTCCC GACTCAG F: ACTGTAGGAGCTA GTGCATTTGT R: TGGATACTTTTGTCT ATCTTTTTCATCAAC	190
Multiplex 3	<i>see</i>	F: CAAAGAAATGCTTTA	482
	<i>seb</i>	AGCAATCTTAGC	404
	<i>sem</i>	R: CACCTTACCGCCAAAGCTG F: ATTCTATTAAGGACA CTAAGTTAGGGA R: ATCCCGTTTCATAAGGCGAGT F: CTATTAATCTTTGG GTTAATGGAGAAC R: TTCAGTTTCGACAG TTTTGTTGTCAT	326
Multiplex 4	<i>sen</i>	F: CGTGGCAATTAGACGAGTC	474
	<i>seq</i>	R: GACTCGTCTAATTGCCACG	204
	<i>sej</i>	F: ACCTGAAAAGCTTCAAGGA R: CGCCAACGTAATTCCAC F: TCAGAACTGTTGTTCCGCTAG R: GAATTTTACCAYCAAAGGTAC	138
Multiplex 5	<i>sep</i>	F: GAATTGCAGGGAAGTCT	182
	<i>seu</i>	R: GGCGGTGTCTTTTGAAC	215
	<i>ser</i>	F: AATGGCTCTAAAATGATGG R: ATTTGATTTCCATCATGCTC F: AGCGGTAATAGCAGAAAATG R: TCTTGTACCGTAACCGTTTT	363
Multiplex 6	<i>TSST</i>	F: TTCACTATTTGTAAA	180
	<i>sel</i>	AGTGTGACACCCACT	234
	<i>sei</i>	R: TACTAATGAATTTTT TTATCGTAAGCCCTT F: GCGATGTAGGTCCAGGAAAC R: CATATATAGTACGA GAGTTAGAACCATA F: CTAGCGGAACAACAGTTCTGA R: AGGCAGTCCATCTCCTG	461
Multiplex 7	<i>seg</i>	F: TCTCCACCTGTTGAAGG	323
	<i>sek</i>	R: AAGTGATTGTCTATTGTCTG	134
	<i>sec</i>	F: ATGCCAGCGCTCAAGGC R: AGATTCATTTGAAAA TTGTAGTTGATTAGCT F: CTTGTATGTATGGAGG AATAACAAAACATG R: CATATCATACCAAAA AGTATTGCCGT	275

PCR: polymerase chain reaction; TSST: toxic shock syndrome toxin.

One sample of each enterotoxin, as well as *mecA* PCR products (amplicons), was sequenced by Bioneer

Co., Korea mediated by Takapouzist Co., Iran and the data were analyzed using the Chromas software.

Table 2: The distribution of isolates among clinical specimens.

Samples	MRSA	MSSA	Total
Sputum	19	9	28
Pus	3	1	4
Blood	40	18	58
Puncture	15	6	21
Urine	21	11	32
Pharyngeal swabs	2	5	7
Nasal swabs	0	50	50
Total	100	100	200

MRSA: methicillin-resistant staphylococcal aureus; MSSA: methicillin-sensitive *S. aureus*.

Data was analyzed using SPSS Statistics (SPSS Inc. Released 2007. SPSS for Windows, Version 11.0. Chicago, SPSS Inc). Descriptive statistical methods were used to determine the frequency, percentage, and mean. Chi-square test was used to compare the qualitative results, and independent *t*-test to compare quantitative data. A *p*-value ≤ 0.050 was considered significant in comparative data.

RESULTS

Among the 200 specimens, the total number of samples from males was 105 (52.5%) and 95 from females (47.5%). The distribution of isolates among the samples is shown in Table 2.

The results of antibiotic resistance of MRSA and MSSA isolates have been presented in Table 3. Chi-squared analysis of the presence of the virulence and

resistance genes showed preferential distribution to MRSA in comparison with MSSA isolates ($p \leq 0.050$). There was a significant relationship between the pathogenicity of MSSA and MRSA and the presence of antibiotics resistance agents.

In our study, MRSA isolates were more prevalent in males (54.0%) than females (46.0%), whereas MSSA isolates were more prevalent in females (59.0%) than males (41.0%) with no significant statistical difference ($p = 0.109$). There was no significant association of MRSA and MSSA with age ($p = 0.126$).

The distribution of *SAg* genes among MRSA and MSSA strains is presented in Table 4. Among MRSA isolates, 92 (92.0%) harbored *SAg* genes and the most frequent toxin gene was *sea* (45.0%), followed by *sec* (39.0%). Among MSSA isolates, 89 (89.0%) harbored *SAg* genes and the most prevalent genes were *sea* 42 (42.0%), *sek* 38 (38.0%), *sec* 35 (35.0%), and *TSST-1*, which were harbored by 10.0% of strains. None of the investigated isolates carried the *eta* gene. The *etd* gene in MRSA was detected only in two strains that belonged to puncture samples. In MSSA, *etd* was detected in two strains isolated from blood and puncture samples. The association of *SAg* genes with MRSA and MSSA isolates showed a higher prevalence of enterotoxin *seq*, *seg*, and *sei* in MRSA than MSSA with significant difference ($p = 0.014$), ($p = 0.001$) and ($p = 0.009$), respectively [Table 4]. There were no significant difference among MRSA and MSSA with other *SAg* ($p > 0.050$).

The results of the basic local alignment search tool (BLAST) of intended genes product indicated

Table 3: The pattern of antibiotics resistance among 100 MRSA and 100 MSSA isolates.

Antibiotics	Antibiotic resistance of MRSA and MSSA clinical isolates, n (%)			
	MRSA	MSSA	Overall resistance	<i>p</i> -value
Tetracycline	91 (91.0)	52 (52.0)	143 (71.5)	< 0.001
Gentamycin	90 (90.0)	25 (25.0)	115 (57.5)	0.009
Erythromycin	92 (92.0)	68 (68.0)	160 (80.0)	< 0.001
Vancomycin	-	-	-	-
Cefoxitin	100 (100)	-	100 (50.0)	< 0.001
Clindamycin	80 (80.0)	46 (46.0)	126 (63.0)	0.001
Ciprofloxacin	95 (95.0)	66 (66.0)	161 (80.5)	< 0.001
TMP/SMX	85 (85.0)	66 (66.0)	151 (75.5)	< 0.001
Rifampin	85 (85.0)	45 (45.0)	130 (65.0)	< 0.001

TMP/SMX: trimethoprim-sulfamethoxazole; MRSA: methicillin-resistant staphylococcal aureus; MSSA: methicillin-sensitive *S. aureus*.

Table 4: Prevalence of *SAg* genes among 100 MRSA and 100 MSSA strains, n (%).

Toxin gene	MRSA	MSSA	Total	p-value
<i>sea</i>	45 (45.0)	42 (42.0)	87 (43.5)	0.097
<i>seb</i>	34 (34.0)	31 (31.0)	65 (32.5)	0.190
<i>sec</i>	39 (39.0)	35 (35.0)	74 (37.0)	0.067
<i>sed</i>	32 (32.0)	28 (28.0)	60 (30.0)	0.066
<i>see</i>	23 (23.0)	22 (22.0)	45 (22.5)	0.351
<i>seh</i>	34 (34.0)	24 (24.0)	58 (29.0)	0.297
<i>sek</i>	34 (34.0)	38 (38.0)	72 (36.0)	0.771
<i>sel</i>	20 (20.0)	22 (22.0)	42 (21.0)	0.581
<i>sej</i>	15 (15.0)	18 (18.0)	33 (16.5)	0.186
<i>sem</i>	19 (19.0)	21 (21.0)	40 (20.0)	0.911
<i>sen</i>	17 (17.0)	20 (20.0)	37 (18.5)	0.472
<i>seo</i>	22 (22.0)	20 (20.0)	42 (21.0)	0.071
<i>sep</i>	24 (24.0)	22 (22.0)	46 (23.0)	0.945
<i>seq</i>	34 (34.0)	22 (22.0)	56 (28.0)	0.014
<i>ser</i>	14 (14.0)	16 (16.0)	30 (15.0)	0.413
<i>seu</i>	26 (26.0)	23 (23.0)	49 (24.5)	0.852
<i>seg</i>	21 (21.0)	13 (13.0)	34 (17.0)	0.001
<i>sei</i>	21 (21.0)	15 (15.0)	36 (18.0)	0.009
<i>etd</i>	2 (2.0)	2 (2.0)	4 (2.0)	0.360
<i>TSST-1</i>	12 (12.0)	10 (10.0)	22 (11.0)	0.058

MRSA: methicilin-resistant staphylococcus aureus; MSSA: methicilin-resistant *S. aureus*; TSST: toxic shock syndrome toxin.

that it has the same DNA sequences and all PCR assay results were confirmed.

DISCUSSION

In this study, the frequency of MRSA among *S. aureus* isolates was 50.0%. Our results are in agreement with another study from Shiraz that reported a MRSA prevalence of 42.3%.²⁰ Among the 100 confirmed MRSA isolates, 46 (46.0%) and 54 (54.0%) were isolated from females and males, respectively, which is similar to previous findings in Shiraz, Iran.²⁰ In addition, higher numbers of MRSA was observed in patients aged 45–60 and 15–30 years old, which is consistent with the results from a Malaysian study.²¹ Studies on the prevalence of MRSA isolates in clinical samples are inconsistent. Some studies, such as our results, indicated a higher prevalence of MRSA in blood (40.0%) and very low rates (5.0%) in pus and pharyngeal swabs samples. In the study performed by Alfatemi et al,²⁰ most cases of MRSA (39.79%) were obtained from sputum and the fewest number (2.05%) were gathered from eye and nose samples. A higher percentage of MRSA was found in blood

and urine than other specimens was similar to other studies.^{21,22}

Most MRSA isolates were multiple-drug resistant. Resistance to TE and GM was higher in MRSA isolates than MSSA isolates, which in conflict with Asadollahi et al,²³ study. Although some investigations in the recent years have reported increasing number of VAN-resistant MRSA isolates, the results of the current study showed that VAN is still the main antibiotic of choice for treatment of serious and threatening infections caused by MRSA and MSSA isolates. Our results also demonstrated that all isolates were susceptible to VAN, which is in agreement with another study from Iran.²³

Studies on the prevalence of enterotoxin gene in MRSA and MSSA isolates are inconsistent. We observed a significant association among the blood samples and high prevalence of enterotoxin in blood ($p = 0.001$) were observed, while there was no significant relationship between *SAg* with other samples ($p > 0.050$). The frequency of the *sea* gene in MRSA isolates from various specimens in our study was 45.0%. This figure is similar to studies performed in Tehran (32.07%),²⁴ Gorgan (58.8%),²⁵ and Shiraz (27.39%),²⁰ Iran, but higher than that

of a study from Germany (12%),¹⁷ Ilam (17%),²³ Iran, and Korea (17.5%).²⁶ Report of *sea* (35.4%) gene prevalence in China was consistent with our result.¹⁹ In our study, the frequency of the *seb* gene was 34.0%, which was inconsistent with other studies in Iran (Gorgan 61.3%,²⁵ Ilam 2%,²³ and Tehran 73.58%)²⁷ and studies from other countries (China 5%,²⁸ Canada 15.78%).²⁹ These differences could be associated with geographical differences, number of samples, and year. The frequency rates of *sed* gene in studies performed in Tehran,²⁸ Shiraz,²⁰ Korea,³⁰ and Columbia,³¹ were 3.77%, 2.05%, 2.9%, and 7%, respectively.

In this study, 90.5% of isolates carried at least one type of enterotoxin. This result was inconsistent with the results obtained by Asadollahi et al.,²³ and in accordance with Alfatemi et al.²⁰ These discrepancies might be due to the different study locations. There was no significant correlation between enterotoxins of MRSA and MSSA strains observed, except for *seq*, *seg*, and *sei*, which had a statistically significant difference $p = 0.014$, $p = 0.001$ and $p = 0.009$, respectively.

The frequency of *TSST-1* gene in MRSA strains in our study was 12.0%, which were obtained from blood (8%) and nasal septal (4%). Our results were consistent with a study from Shiraz (11.64%)²⁰ and Germany (9.14%),¹⁷ and conflicting with those from Ilam (46%)²³ and several other countries (Korea 72.2%, Czech 50%, and 0–78% in the US). In our study, none of the investigated isolates harbored the *eta* gene. The frequency rates of *eta* gene in different studies from Iran were very low (Shiraz and Ilam were 0.68% and 1%, respectively).^{20,23} This was also the finding in other countries including Germany, Turkey, and Colombia³¹ (2%, 19.2%, and 3%, respectively). Furthermore, in our study, the frequency rate of *etd* gene in all strains of *S. aureus* was 2.0%, while the *etd* gene was not found in any of the isolates tested by Wu et al.¹⁹ The frequency of MRSA enterotoxin genes in different countries and even within a country in different cities or hospitals, have not been determined to be the same. This could be due to differences in the geographical features of each country, the hospital wards where the specimens collected from, number of samples, patients, and health conditions.

One of the strengths of our study compared to similar studies is the number of clinical samples taken from different locations and also the

application of seven multiplex PCR complex for detection more than of 20 Staphylococcus toxin genes. Our study is limited by not using advanced typing methods such as pulsed-field gel electrophoresis or multilocus sequence typing for epidemiological interpretation.

CONCLUSIONS

Our isolates exhibited a high rate of resistance to CIP and TMP/SMX. There is a significant relationship between virulence genes and antibiotic resistance patterns. Genetic investigations of clinical MRSA and MSSA could provide a global and comprehensive aspect of risk prediction, which can be suitable for short-term and long-term health care policies.

Disclosure

The authors declared no conflicts of interest. The authors would like to acknowledge the Vice Chancellor of Hamadan University of Medical Sciences for funding of the current study.

REFERENCES

1. Pesavento G, Ducci B, Comodo N, Nostro AL. Antimicrobial resistance profile of Staphylococcus aureus isolated from raw meat: A research for methicillin resistant staphylococcus aureus (MRSA). Food Control 2007;18(3):196-200.
2. Foster TJ, Höök M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 1998 Dec;6(12):484-488.
3. Peles F, Wagner M, Varga L, Hein I, Rieck P, Gutser K, et al. Characterization of Staphylococcus aureus strains isolated from bovine milk in Hungary. Int J Food Microbiol 2007 Sep;118(2):186-193.
4. Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food Microbiol 2000 Oct;61(1):1-10.
5. Batchelor FR, Cameron-Wood J, Chain EB, Rolinson GN. 6-Aminopenicillanic acid. V. 6-Aminopenicillanic acid as a substrate for penicillinase and an inducer of penicillinase formation. Proc R Soc Lond B Biol Sci 1961 Aug;154:514-521.
6. Townsend DE, Ashdown N, Bolton S, Bradley J, Duckworth G, Moorhouse EC, et al. The international spread of methicillin-resistant Staphylococcus aureus. J Hosp Infect 1987 Jan;9(1):60-71.
7. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al; SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001 May;32(Suppl 2):S114-S132.
8. Omoe K, Hu D-L, Takahashi-Omoe H, Nakane A, Shinagawa K. Comprehensive analysis of classical and newly described staphylococcal superantigenic toxin genes in Staphylococcus aureus isolates. FEMS microbiol lett 2005;246(2):191-198.
9. Novick RP. Mobile genetic elements and bacterial toxinoses: the superantigen-encoding pathogenicity islands of Staphylococcus aureus. Plasmid 2003 Mar;49(2):93-105.
10. Argudín MÁ, Mendoza MC, Rodicio MR. Food poisoning and Staphylococcus aureus enterotoxins. Toxins (Basel)

- 2010 Jul;2(7):1751-1773.
11. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome *Staphylococcus aureus* isolates. *Lancet* 1981 May;1(8228):1017-1021.
 12. Okuma K, Iwakawa K, Turnidge JD, Grubb WB, Bell JM, O'Brien FG, et al. Dissemination of new methicillin-resistant *Staphylococcus aureus* clones in the community. *J Clin Microbiol* 2002 Nov;40(11):4289-4294.
 13. Hu D-L, Omoe K, Inoue F, Kasai T, Yasujima M, Shinagawa K, et al. Comparative prevalence of superantigenic toxin genes in methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* isolates. *J Med Microbiol* 2008 Sep;57(Pt 9):1106-1112.
 14. Holtfreter S, Bauer K, Thomas D, Feig C, Lorenz V, Roschack K, et al. egc-Encoded superantigens from *Staphylococcus aureus* are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. *Infect Immun* 2004 Jul;72(7):4061-4071.
 15. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol* 2000 Mar;38(3):1008-1015.
 16. Mashouf RY, Hosseini SM, Mousavi SM, Arabestani MR. Prevalence of enterotoxin genes and antibacterial susceptibility pattern of *Staphylococcus aureus* strains isolated from animal originated foods in west of Iran. *Oman Med J* 2015 Jul;30(4):283-290.
 17. Cockerill FR. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Clinical and Laboratory Standards Institute (CLSI); 2011.
 18. Goerke C, Pantucek R, Holtfreter S, Schulte B, Zink M, Grumann D, et al. Diversity of prophages in dominant *Staphylococcus aureus* clonal lineages. *J Bacteriol* 2009 Jun;191(11):3462-3468.
 19. Wu D, Li X, Yang Y, Zheng Y, Wang C, Deng L, et al. Superantigen gene profiles and presence of exfoliative toxin genes in community-acquired methicillin-resistant *Staphylococcus aureus* isolated from Chinese children. *J Med Microbiol* 2011 Jan;60(Pt 1):35-45.
 20. Hoseini Alfatehi SM, Motamedifar M, Hadi N, Sedigh Ebrahim Saraie H. Analysis of virulence genes among methicillin resistant *Staphylococcus aureus* (MRSA) strains. *Jundishapur J Microbiol* 2014 Jun;7(6):e10741.
 21. Neela V, Ghasemzadeh Moghaddam H, van Belkum A, Horst-Kreft D, Mariana NS, Ghaznavi Rad E. First report on methicillin-resistant *Staphylococcus aureus* of Spa type T037, Sequence Type 239, SCCmec type III/IIIA in Malaysia. *Eur J Clin Microbiol Infect Dis* 2010 Jan;29(1):115-117.
 22. Tiwari HK, Das AK, Sapkota D, Sivrajan K, Pahwa VK. Methicillin resistant *Staphylococcus aureus*: prevalence and antibiogram in a tertiary care hospital in western Nepal. *J Infect Dev Ctries* 2009 Oct;3(9):681-684.
 23. Asadollahi P, Delpisheh A, Maleki MH, Jalilian FA, Alikhani MY, Asadollahi K, et al. Enterotoxin and Exfoliative Toxin Genes Among Methicillin-Resistant *Staphylococcus aureus* Isolates Recovered From Ilam, Iran. *Avicenna J Clin Microb Infect* 2014;1(2):e20208.
 24. Fatholahzadeh B, Emaneini M, Gilbert G, Udo E, Aligholi M, Modarresi MH, et al. Staphylococcal cassette chromosome mec (SCCmec) analysis and antimicrobial susceptibility patterns of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates in Tehran, Iran. *Microb Drug Resist* 2008 Sep;14(3):217-220.
 25. Kamarehei F, Ghaemi EA, Dadgar T. Prevalence of enterotoxin A and B genes in *Staphylococcus aureus* isolated from clinical samples and healthy carriers in Gorgan City, North of Iran. *Indian J Pathol Microbiol* 2013 Jul-Sep;56(3):265-268.
 26. Kim JS, Song W, Kim HS, Cho HC, Lee KM, Choi MS, et al. Association between the methicillin resistance of clinical isolates of *Staphylococcus aureus*, their staphylococcal cassette chromosome mec (SCCmec) subtype classification, and their toxin gene profiles. *Diagn Microbiol Infect Dis* 2006 Nov;56(3):289-295.
 27. Norouzi J, Goudarzi G. The isolation and detection of *Staphylococcus aureus* enterotoxins AE and TSST-1 genes from different sources by PCR method. *Qom Uni Med Sci J* 2012;6(3):78-85.
 28. Wang LX, Hu ZD, Hu YM, Tian B, Li J, Wang FX, et al. Molecular analysis and frequency of *Staphylococcus aureus* virulence genes isolated from bloodstream infections in a teaching hospital in Tianjin, China. *Genet Mol Res* 2013 Mar;12(1):646-654.
 29. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *J Clin Microbiol* 2000 Mar;38(3):1032-1035.
 30. Peck KR, Baek JY, Song J-H, Ko KS. Comparison of genotypes and enterotoxin genes between *Staphylococcus aureus* isolates from blood and nasal colonizers in a Korean hospital. *J Korean Med Sci* 2009 Aug;24(4):585-591.
 31. Smyth RW, Kahlmeter G. Mannitol salt agar-cefoxitin combination as a screening medium for methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2005 Aug;43(8):3797-3799.